Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study.

IF 2.3 3区医学 Q3 ONCOLOGY

Thoracic Cancer Pub Date : 2025-07-01 DOI:10.1111/1759-7714.70118

Ayako Shiono, Hisao Imai, Kyoichi Kaira, Takanori Abe, Yuki Sato, Ken Yamamoto, Hiroki Watanabe, Yuko Tsuchiya-Kawano, Akihiro Tamiya, Takashi Osaki, Noriko Yanagitani, Shigeru Tanzawa, Toshiyuki Sumi, Kohei Yoshimine, Yohei Matsui, Satoshi Endo, Kazuhiko Shibata, Shinnosuke Takemoto, Yosuke Miura, Yoshiaki Nagai, Junichi Nakagawa, Takeshi Tsuda, Hiroshi Kagamu

{"title":"Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study.","authors":"Ayako Shiono, Hisao Imai, Kyoichi Kaira, Takanori Abe, Yuki Sato, Ken Yamamoto, Hiroki Watanabe, Yuko Tsuchiya-Kawano, Akihiro Tamiya, Takashi Osaki, Noriko Yanagitani, Shigeru Tanzawa, Toshiyuki Sumi, Kohei Yoshimine, Yohei Matsui, Satoshi Endo, Kazuhiko Shibata, Shinnosuke Takemoto, Yosuke Miura, Yoshiaki Nagai, Junichi Nakagawa, Takeshi Tsuda, Hiroshi Kagamu","doi":"10.1111/1759-7714.70118","DOIUrl":null,"url":null,"abstract":"Main problem: The efficacy and safety of platinum-based chemotherapy with programmed death-1 (PD-1) blockade after chemoradiotherapy (CRT) for the treatment of limited disease (LD) small cell lung cancer (SCLC) is unknown. This study aimed to assess the effectiveness and tolerability of platinum-based chemotherapy with PD-1 blockade in patients with recurrent LD-SCLC after CRT.Methods: This retrospective study analyzed 66 patients who experienced recurrence after CRT for LD-SCLC and received platinum-based chemotherapy with PD-1 blockade therapy between August 2019 and September 2020 at 19 Japanese institutions. Clinical efficacy was assessed according to response rate, survival, and toxicity.Results: The overall response rate was 53.0% (95% confidence interval [CI], 48.9-65.0), and the disease control rate was 78.7% (95% CI, 68.9-88.5). The median progression-free survival and overall survival periods were 5.9 (95% CI, 4.7-7.3) months and 24.9 (95% CI, 16.8-28.1) months, respectively. The frequencies of grade ≥ 3 hematological adverse events were as follows: leukopenia, 47.0%; neutropenia, 65.2%; and febrile neutropenia, 8.3%. There was no treatment-related death.Conclusions: Chemoimmunotherapy is a feasible and effective treatment for recurrent disease after CRT in patients with LD-SCLC, providing a new potential option for the pharmacological management of these patients.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 13","pages":"e70118"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207248/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thoracic Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1759-7714.70118","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Main problem: The efficacy and safety of platinum-based chemotherapy with programmed death-1 (PD-1) blockade after chemoradiotherapy (CRT) for the treatment of limited disease (LD) small cell lung cancer (SCLC) is unknown. This study aimed to assess the effectiveness and tolerability of platinum-based chemotherapy with PD-1 blockade in patients with recurrent LD-SCLC after CRT.

Methods: This retrospective study analyzed 66 patients who experienced recurrence after CRT for LD-SCLC and received platinum-based chemotherapy with PD-1 blockade therapy between August 2019 and September 2020 at 19 Japanese institutions. Clinical efficacy was assessed according to response rate, survival, and toxicity.

Results: The overall response rate was 53.0% (95% confidence interval [CI], 48.9-65.0), and the disease control rate was 78.7% (95% CI, 68.9-88.5). The median progression-free survival and overall survival periods were 5.9 (95% CI, 4.7-7.3) months and 24.9 (95% CI, 16.8-28.1) months, respectively. The frequencies of grade ≥ 3 hematological adverse events were as follows: leukopenia, 47.0%; neutropenia, 65.2%; and febrile neutropenia, 8.3%. There was no treatment-related death.

Conclusions: Chemoimmunotherapy is a feasible and effective treatment for recurrent disease after CRT in patients with LD-SCLC, providing a new potential option for the pharmacological management of these patients.

查看原文本刊更多论文

以铂为基础的程序性死亡-1阻断化疗在有限疾病小细胞肺癌中的意义：一项回顾性研究

主要问题：放化疗（CRT）后铂基化疗伴程序性死亡-1 （PD-1）阻断治疗局限性疾病（LD）小细胞肺癌（SCLC）的有效性和安全性尚不清楚。本研究旨在评估CRT后复发性LD-SCLC患者铂类化疗联合PD-1阻断治疗的有效性和耐受性。方法：本回顾性研究分析了2019年8月至2020年9月在日本19家机构接受PD-1阻断治疗的66例LD-SCLC CRT后复发并接受铂类化疗的患者。根据有效率、生存期和毒性评估临床疗效。结果：总有效率为53.0%(95%可信区间[CI] 48.9 ~ 65.0)，疾病控制率为78.7% （95% CI 68.9 ~ 88.5）。中位无进展生存期和总生存期分别为5.9 （95% CI, 4.7-7.3）个月和24.9 （95% CI, 16.8-28.1）个月。3级以上血液学不良事件发生率：白细胞减少，47.0%；嗜中性白血球减少症,65.2%;发热性中性粒细胞减少症，8.3%。没有治疗相关的死亡。结论：化疗免疫治疗是治疗LD-SCLC患者CRT后复发疾病的一种可行有效的治疗方法，为这类患者的药物管理提供了一种新的潜在选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Thoracic Cancer ONCOLOGY-RESPIRATORY SYSTEM

CiteScore

5.20

自引率

3.40%

发文量

439

审稿时长

2 months

期刊介绍： Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society. The Journal publishes a range of article types including: Editorials, Invited Reviews, Mini Reviews, Original Articles, Clinical Guidelines, Technological Notes, Imaging in thoracic cancer, Meeting Reports, Case Reports, Letters to the Editor, Commentaries, and Brief Reports.